Sage Therapeutics (NASDAQ:SAGE) Stock Rating Upgraded by Baird R W

Sage Therapeutics (NASDAQ:SAGEGet Free Report) was upgraded by research analysts at Baird R W to a “hold” rating in a report issued on Wednesday, Zacks.com reports.

A number of other equities analysts have also commented on the stock. Morgan Stanley raised their price objective on shares of Sage Therapeutics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 28th. Bank of America lowered shares of Sage Therapeutics from a “neutral” rating to an “underperform” rating and decreased their target price for the company from $24.00 to $14.00 in a research note on Wednesday, April 17th. JPMorgan Chase & Co. decreased their target price on shares of Sage Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research note on Wednesday, May 1st. HC Wainwright decreased their target price on shares of Sage Therapeutics from $28.00 to $25.00 and set a “neutral” rating for the company in a research note on Friday, April 26th. Finally, Canaccord Genuity Group decreased their target price on shares of Sage Therapeutics from $21.00 to $17.00 and set a “hold” rating for the company in a research note on Friday, April 26th. Two investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Sage Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $35.05.

Get Our Latest Stock Report on Sage Therapeutics

Sage Therapeutics Stock Performance

Sage Therapeutics stock opened at $11.50 on Wednesday. The company has a 50 day moving average price of $14.42 and a 200 day moving average price of $19.57. Sage Therapeutics has a 52 week low of $10.78 and a 52 week high of $59.99. The firm has a market capitalization of $692.07 million, a price-to-earnings ratio of -1.36 and a beta of 0.91.

Sage Therapeutics (NASDAQ:SAGEGet Free Report) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). Sage Therapeutics had a negative return on equity of 56.81% and a negative net margin of 552.52%. The firm had revenue of $7.90 million during the quarter, compared to analyst estimates of $5.26 million. During the same period in the prior year, the business posted ($2.46) EPS. The company’s revenue for the quarter was up 139.4% on a year-over-year basis. Equities analysts forecast that Sage Therapeutics will post -6.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Lazard Asset Management LLC bought a new position in Sage Therapeutics in the 1st quarter worth $127,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Sage Therapeutics by 353.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,937 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 5,406 shares during the period. Virtu Financial LLC bought a new position in shares of Sage Therapeutics during the 1st quarter worth about $187,000. Values First Advisors Inc. bought a new position in shares of Sage Therapeutics during the 3rd quarter worth about $219,000. Finally, Quest Partners LLC bought a new position in shares of Sage Therapeutics during the 4th quarter worth about $261,000. Institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

(Get Free Report)

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.

Featured Stories

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.